Alzinova Ab · OMXSTO:ALZ
Alzinova Ab — Investor Presentation (May 2022)
27 slides from Alzinova Ab's investor presentation, May 6, 2022
Slide 1: Company presentation
alzinova Company presentation
Slide 2: Forward looking statements
Forward looking statements This information contains forward-looking statements that reflect the Company's intentions, beliefs, or current expectations about and targets for the Company's future results of operations, financial condition, liquidity, performance, prospects, anticipated growth, strate
Slide 3: Imagine if there was a vaccine against Alzheimer's disease
Imagine if there was a 3 vaccine against Alzheimer's disease
Slide 4: Alzinova is developing the first oligomer-specific vaccine against Alzheimer's disease
Alzinova is developing the first oligomer-specific vaccine against Alzheimer’s disease Swedish biopharma company Based in Gothenburg. Founded: 2011 High unmet medical need for Alzheimer’s disease Innovative science and proprietary technology enables development of disease-modifying treatments for Al
Slide 5: Alzheimer's disease is a progressively debilitating disease with a huge unmet medical need
Alzheimer’s disease is a progressively debilitating disease with a huge unmet medical need >55 million people have dementia, >150 million in 2050. (Alzheimer’s = 60-70% of all dementia) Impacts quality of life for patients, their families and care givers Annual cost of dementia US $1.3 trillion (US
Slide 6: Enormous market potential. Blockbuster status predicted for Alzheimer's treatments by 2026
Enormous market potential. “Blockbuster status” predicted for Alzheimer’s treatments by 2026 Alzheimer’s therapeutics market = US $13 billion by 2028 Sales and revenue potential of a new drug is substantial Two of 7 predicted blockbusters by 2026 are new anti- Alzheimer’s drugs with US $1.7 - 4.5 bi
Slide 7: Best-in-class potential. Creates strong position for Alzinova to take market share
Best-in-class potential. Creates strong position for Alzinova to take market share in a growing market Non-specific binding Non-specific binding Specific binding Selectivity for aggregated Aβ Oligomer-specific targeting Aβ40 Aβ42 Toxic forms (oligomers) Insoluble Aβ forms (fibrils) Side effects (ARI
Slide 8: Alzinova's AβCC peptide technology enables high precision, disease-modifying therapies
Alzinova’s AβCC peptide™ technology enables development of high precision, disease-modifying therapies specifically targeting the neurotoxic oligomers Aβ – amyloid-beta 8 ©2022 Alzinova AB (publ), All rights reserved
Slide 9: Alzinova is developing two oligomer-specific products based on the same proprietary technology
Alzinova is developing two oligomer-specific products based on the same proprietary technology • Highly specific disease modifying therapeutics, directed towards the neurotoxic oligomeric amyloid beta • Opportunity to become an effective and well tolerated treatment to halt and prevent Alzheimer’s •
Slide 10: ALZ-101 and ALZ-201 represent a potential breakthrough in Alzheimer's Disease
ALZ-101 and ALZ-201 represent a potential breakthrough in Alzheimer's Disease • ALZ-101 vaccine • ALZ-201 monoclonal antibody − High patient compliance (few booster doses) − Accurate antibody dosing − Long-acting − Lower doses (vs. non-specific antibody) − Preventive treatment possible − Well tolera
Slide 11: Alzinova's product pipeline offers complementary ways to fight Alzheimer's Disease
Alzinova's product pipeline offers complementary ways to fight Alzheimer’s Disease Candidates Discovery Pre-clinical Clinical NDA/MAA Next Planned Milestone ALZ-1011) therapeutic H2 2023 Topline data vaccine clinical phase 1b ALZ-2012) monoclonal antibody TBD “Phase 1 ready” New innovative discovery
Slide 12: ALZ-101 is differentiated from other immunotherapies developed against Alzheimer's Disease
ALZ-101 is differentiated from other immunotherapies developed against Alzheimer's Disease • Highly specific therapeutic vaccine, directed towards the neurotoxic oligomeric Aβ • Opportunity to become an effective and well tolerated treatment to halt and prevent Alzheimer’s • Long-acting and cost-eff
Slide 13: Strong data supports clinical development of ALZ-101
Strong data supports clinical development of ALZ-101 Transgenic mice vaccinated with ALZ-101 • Comprehensive pre-clinical package showed a 25% increase of synapse density compared to controls – ALZ-101 is well tolerated in non-clinical safety and toxicity studies (monkeys and rabbits) ✓ – Efficacy d
Slide 14: ALZ-101 Phase 1b clinical study in patients with Alzheimer's disease
ALZ-101 Phase 1b clinical study in patients with Alzheimer’s disease 20-week study with ALZ-101 (125 and 250 μg) or placebo, given at weeks 0, 4, 8 and 16 with a follow-up period of 48 weeks ALZ-101 Endpoints: 125 μg N=10 Primary: safety, tolerability ALZ-101 Secondary: Immunogenicity 26 subjects R
Slide 15: ALZ-201 monoclonal antibody is different from known antibodies
ALZ-201 monoclonal antibody is different from known antibodies • ALZ-201 has a binding profile that differs from known antibodies • Targets a very small fraction of all Aβ with a profound effect on the neurotoxic oligomeric Aβ • The toxic form of Aβ is very low in brain and high selectivity is likel
Slide 16: ALZ-201 in the portfolio of disease-modifying therapies against Alzheimer's disease
ALZ-201 in the portfolio of disease-modifying therapies against Alzheimer’s disease. • ALZ-201, a monoclonal antibody, differentiated from other immunotherapies developed against Alzheimer’s − Highly specific, directed towards the neurotoxic oligomeric Aβ − Opportunity to become an effective and wel
Slide 17: Development of vaccine ALZ-101 and monoclonal antibody ALZ-201 - a three-pronged approach
Development of vaccine ALZ-101 and monoclonal antibody ALZ-201 - a three-pronged approach ALZ-101 vaccine - phase 1b study • 1 year recruitment – ongoing ALZ-101 vaccine – phase 2 ready • Long-term extension study of phase 1b – planning • Process optimization of manufacturing of peptide (ALZ-101) ✓
Slide 18: Alzinova's business model: develop, document, prepare, partner
Alzinova's business model: develop, document, prepare, partner • Develop novel disease-modifying immunotherapies based on proprietary AβCC technology • Document safety and tolerability in patients with Alzheimer’s disease • Prepare (in parallel) for phase 2 to optimize the value of the candidates •
Slide 19: Experienced management team and innovation-focused collaborations
Experienced management team and innovation-focused collaborations Kristina Torfgård, PhD Anders Sandberg, PhD Anders Bylock, MD, PhD Chief Executive Officer Chief Scientific Officer and Chief Medical Officer Co-Founder 30 years experience – >30 years experience – AstraZeneca, Albireo >20 years exper
Slide 20: Board of Directors with extensive pharma and biopharma experience
Board of Directors with extensive pharma and biopharma experience Björn Larsson Anders Blom Per-Göran Gillberg, PhD Chair of the Board >25 years experience – 35 years in experience – >25 years experience – Pharmacia & Upjohn, Q-Med AB, Kabi, Kabi Pharmacia, Pharmacia & Novo Nordisk, AstraZeneca, Nex
Slide 21: Capitalisation table, summary of shares and options
Capitalisation table, summary of shares and options Shareholders, as per 31 March 2022: Capitalization table (amounts in million SEK): Market cap, as per 2 May. 2022 44.0 Share options incentive program 2020/2023 (SEK 22,50 WAEP) 3.3 Total, including fully exercised options 47.3 Company management a
Slide 22: Financial information
Financial information amounts in thousand SEK Income statement Cashflow statement Jan-Mar 2022 Jan-Mar 2021 Jan - Dec 2021 Jan-Mar 2022 Jan-Mar 2021 Jan - Dec 2021 SEK 3 months 3 months 12 months SEK 3 months 3 months 12 months Cash flow from operating activities before change in working capital -2,
Slide 23: Financial information
Financial information amounts in thousand SEK Balance sheet SEK 31 Mar 2022 31 Mar 2021 31 Dec 2021 SEK 31 Mar 2022 31 Mar 2021 31 Dec 2021 ASSETS EQUITY AND LIABILITIES Fixed assets Equity Intangible assets Restricted equity Capitalized expenditure for development 66,938 49,653 60,015 Share capital
Slide 24: Alzinova's portfolio offers a potential breakthrough for the treatment of Alzheimer's patients
Summary: Alzinova’s portfolio offers a potential breakthrough for the treatment of Alzheimer’s patients High unmet medical need for disease-modifying treatments of Alzheimer’s disease • Short-term goal: First oligomer-specific clinical trial with a therapeutic vaccine in patients by Q3 2021 ✓ • Mid-
Slide 25: Use of proceeds from the rights issue
Use of proceeds from the rights issue The rights issue In order to finance further development of ALZ-101 and ALZ-201, Alzinova is now carrying out a rights issue of units of approximately SEK 42.5 million. The rights issue is covered to approximately 80 percent through subscription commitments and
Slide 26: Alzinova's rights issue in short
Alzinova’s rights issue in short Step 1 Step 2 Step 3 Summarizing timetable of the rights issue One (1) share held on 25 May gives one (1) unit right. Four (4) unit rights gives the right to subscribe for one (1) One (1) unit consists of five (5) shares and four (4) warrants of series TO3. unit. 1.
Slide 27: Thank you!
alzinova® Thank you!